GlassScriptPhysician profile
Veerpal Singh
NPI 1295952596
$14,793.20
in general payments reported to CMS, 2019-2025
68 companies · $3,303 in 2025
The $3,303 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,193 · 2020: $446 · 2021: $1,256 · 2022: $2,207 · 2023: $2,600 · 2024: $3,788 · 2025: $3,303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,142 · Long Term Medical Supply Or Device Loan: $1,500 · Education: $48.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,142.17 |
| Long Term Medical Supply Or Device Loan | $1,499.94 |
| Education | $48.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,622.17 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $900.67 | 2019-2025 | Lynparza, Enhertu, Imfinzi |
| Merck Sharp & Dohme LLC | $772.07 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $758.00 | 2019-2025 | |
| Abbvie INC. | $620.00 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $592.98 | 2019-2024 | Xarelto |
| Genentech USA, INC. | $499.27 | 2019-2025 | Tecentriq, Lunsumio, Polivy |
| Celgene Corporation | $428.26 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $410.38 | 2019-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Astellas Pharma US INC | $393.36 | 2019-2025 | Vyloy, Padcev, Xospata |
| Daiichi Sankyo INC. | $361.54 | 2020-2025 | Enhertu, Datroway |
| Tempus Ai, INC | $346.07 | 2024-2025 | Xt Cdx |
| Gilead Sciences, INC. | $342.66 | 2021-2025 | Trodelvy |
| Amgen INC. | $297.20 | 2019-2023 | Kyprolis, Blincyto, Xgeva |
| E.R. Squibb & Sons, L.L.C. | $296.88 | 2019-2025 | Opdualag, Opdivo, Eliquis |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $259.75 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Jazz Pharmaceuticals INC. | $244.51 | 2022-2025 | |
| Blueprint Medicines Corporation | $218.19 | 2022-2025 | Ayvakit |
| Genzyme Corporation | $213.49 | 2019-2025 | |
| Octapharma USA, INC. | $212.65 | 2024-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Incyte Corporation | $168.91 | 2020-2025 | Monjuvi |
| Tersera Therapeutics LLC | $167.11 | 2023-2025 | Xermelo, Zoladex |
| Inari Medical, INC. | $157.70 | 2022 | |
| Array Biopharma INC | $140.98 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Agios Pharmaceuticals, INC. | $137.77 | 2020-2025 | Pyrukynd |
| Karyopharm Therapeutics INC. | $133.36 | 2021-2025 | Xpovio |
| Alexion Pharmaceuticals, INC. | $115.73 | 2022-2025 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $111.55 | 2021-2023 | Libtayo |
| Morphosys, US INC. | $105.04 | 2021-2023 | Monjuvi |
| Emd Serono, INC. | $103.95 | 2019-2023 | Tepmetko |
| Pharmacyclics LLC, An Abbvie Company | $98.19 | 2019-2023 | Imbruvica, Epkinly |
| Adaptive Biotechnologies Corporation | $97.12 | 2021-2025 | Clonoseq |
| G1 Therapeutics, INC. | $93.21 | 2022-2023 | Cosela |
| Immunocore Limited | $87.07 | 2024-2025 | Kimmtrak |
| Cti Biopharma Corp. | $85.13 | 2022-2023 | Vonjo |
| Lilly USA, LLC | $79.66 | 2019-2023 | Jaypirca |
| Exelixis INC. | $79.50 | 2019 | |
| Seagen INC. | $71.63 | 2022-2023 | Padcev |
| Dendreon Pharmaceuticals LLC | $70.27 | 2020-2024 | Provenge |
| Puma Biotechnology, INC. | $62.31 | 2023-2024 | Nerlynx |
| Adc Therapeutics America, INC. | $52.90 | 2022-2024 | |
| Janssen Biotech, INC. | $50.83 | 2019-2025 | Rybrevant |
| Novo Nordisk INC | $47.06 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.69 | 2019-2025 | |
| Biocon Biologics INC | $46.57 | 2023-2024 | Ogivri, Hulio |
| Sobi, INC | $43.66 | 2025 | |
| Eisai INC. | $42.07 | 2023 | |
| Pharmacosmos Therapeutics INC. | $41.52 | 2023-2024 | Cosela, Monoferric |
| Clovis Oncology, INC. | $38.10 | 2021 | |
| Kite Pharma, INC. | $32.27 | 2021-2023 | Yescarta |
| Celltrion USA INC. | $30.40 | 2024 | Vegzelma |
| Deciphera Pharmaceuticals INC. | $30.12 | 2022 | |
| Aveo Pharmaceuticals, INC. | $29.55 | 2024 | |
| Ge Healthcare | $27.45 | 2024 | |
| Amag Pharmaceuticals, INC. | $26.65 | 2021 | |
| Alnylam Pharmaceuticals INC. | $25.49 | 2023 | Givlaari |
| Blue Earth Diagnostics | $24.92 | 2022 | |
| Beigene USA, INC. | $24.02 | 2024 | Brukinsa |
| Servier Pharmaceuticals LLC | $21.69 | 2023 | |
| Organon LLC | $20.83 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.90 | 2023 | |
| Myriad Genetic Laboratories, INC. | $19.80 | 2021 | |
| Mylan Institutional INC. | $16.57 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $16.20 | 2025 | Onivyde |
| Bio Products Laboratory USA, INC. | $16.10 | 2023 | Gammaplex, Coagadex |
| Verastem, INC. | $15.84 | 2019 | |
| Fortovia Therapeutics, INC. | $14.98 | 2020 | |
| Taiho Oncology, INC. | $14.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veerpal Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.